Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen sold 39,312 shares of the business’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $18.59, for a total transaction of $730,810.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Amphastar Pharmaceuticals, Inc. (AMPH) traded down 0.11% on Friday, reaching $18.94. The company had a trading volume of 86,049 shares. The stock’s 50-day moving average price is $16.25 and its 200-day moving average price is $16.08. Amphastar Pharmaceuticals, Inc. has a 12-month low of $12.05 and a 12-month high of $21.75. The stock has a market capitalization of $874.93 million, a P/E ratio of 245.97 and a beta of 1.69.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Wednesday, August 9th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.06 by $0.05. Amphastar Pharmaceuticals had a return on equity of 2.42% and a net margin of 1.61%. The business had revenue of $65.20 million during the quarter, compared to the consensus estimate of $63.40 million. During the same quarter last year, the company earned $0.23 EPS. The firm’s revenue was down 4.1% compared to the same quarter last year. On average, equities research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post $0.27 EPS for the current fiscal year.

Amphastar Pharmaceuticals announced that its Board of Directors has initiated a share buyback plan on Wednesday, August 9th that allows the company to buyback $20.00 million in shares. This buyback authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/10/06/amphastar-pharmaceuticals-inc-amph-director-sells-730810-08-in-stock.html.

A number of research analysts recently commented on the company. ValuEngine downgraded Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Piper Jaffray Companies set a $19.00 price target on Amphastar Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. Needham & Company LLC boosted their price target on Amphastar Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, September 27th. Wells Fargo & Company reaffirmed a “buy” rating on shares of Amphastar Pharmaceuticals in a research note on Saturday, July 22nd. Finally, TheStreet raised Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Monday, June 26th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $20.17.

Several institutional investors and hedge funds have recently modified their holdings of the company. Alps Advisors Inc. boosted its position in shares of Amphastar Pharmaceuticals by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 39,250 shares of the company’s stock valued at $701,000 after acquiring an additional 101 shares during the last quarter. Arizona State Retirement System boosted its position in shares of Amphastar Pharmaceuticals by 1.1% during the 1st quarter. Arizona State Retirement System now owns 18,700 shares of the company’s stock valued at $271,000 after acquiring an additional 200 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its position in shares of Amphastar Pharmaceuticals by 2.8% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 8,430 shares of the company’s stock valued at $151,000 after acquiring an additional 230 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Amphastar Pharmaceuticals by 1.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 28,701 shares of the company’s stock valued at $512,000 after acquiring an additional 312 shares during the last quarter. Finally, Mason Street Advisors LLC boosted its position in shares of Amphastar Pharmaceuticals by 7.0% during the 1st quarter. Mason Street Advisors LLC now owns 8,394 shares of the company’s stock valued at $122,000 after acquiring an additional 549 shares during the last quarter. Hedge funds and other institutional investors own 44.26% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.